Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1

Conditions

Multiple Myeloma 1Lymphoma, T-Cell, Peripheral 1Immunoglobulin Light-chain Amyloidosis 1

Interventions

dexamethasone acetate 2dexamethasone 21-phosphate 2auricularum 2Specimen Handling 2Magnetic Resonance Spectroscopy 2Dexamethasone 2Calcium Dobesilate 2Biopsy 24-(N-methylamino)-4'-(2-(2-(2-fluoroethoxy)ethoxy)ethoxy)stilbene 2venetoclax 1ixazomib 1daratumumab 1belantamab mafodotin 1X-Rays 1Stem Cell Transplantation 1Phantoms, Imaging 1Melphalan 1Cyclophosphamide 1Bortezomib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Immunoglobulin Light-chain Amyloidosis × ixazomib × 30 days × Clear all
NCT04847453 2026-05-13

Venetoclax, MLN9708 (Ixazomib Citrate) and Dexamethasone for the Treatment of Relapsed or Refractory Light Chain Amyloidosis

National Cancer Institute (NCI)

Phase 1 Active not recruiting
24 enrolled
Plasma cell

Immunoglobulin Light-chain Amyloidosis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡